As a result Neulasta was still Amgen’s second biggest selling drug last year, with the US accounting for nearly $3.9 billion in sales, with only $609 million coming from the rest of the world.

Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion ...

This leaflet answers some common questions about Neulasta. It does not contain all the available information. It does not take the place of talking to your doctor, nurse or pharmacist. All ...

Both stocks have been in the limelight lately, given their focus on the lucrative weight-loss treatment market.

They are not sisters in the literal sense, but the women who run the Red Carpet Warriors fundraiser have such a tight bond ...

Q1 2024 Earnings Call Transcript May 10, 2024. CHRS isn’t one of the 30 most popular stocks among hedge funds at the end of ...

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and ...

Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) ...

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and ...

VARENNES, QC, April 19, 2024 /CNW/ - Nora Pharma, a Canadian pharmaceutical company, has received approval for its first Biosimilar product. Nora Pharma, a wholly owned division of Sunshine ...

– New $38.7 million term loan with a May 2029 maturity– – $37.5 million royalty monetization financing based on future sales of LOQTORZI ® and UDENYCA ® – REDWOOD CITY, Calif., May 09, 2024 (GLOBE ...